The Food and Drug Administration granted accelerated approval on Wednesday for a new drug developed by researchers at the ...
Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...
The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...
13hon MSN
Sneaky senescent cells that resist cancer treatment can provide druggable lung cancer target
Senescent fibroblasts are aging cells that no longer divide and protect against tumor development. Yet two decades have gone ...
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
MedPage Today on MSN
New FDA-Approved Option for HER2-Mutated Lung Cancer
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The government has approved new reimbursement rules enabling patients with advanced non-small cell lung cancer (NSCLC) to use ...
Nuvalent filed a new drug application for an experimental non-small cell lung cancer treatment with the Food and Drug Administration.
3don MSNOpinion
He's a leading expert in nonsmoker lung cancer. After he got the disease, insurance denied his treatment
OPINION: Stanford Dr. Bryant Lin is both a patient and an advocate in yet another vexing health care problem: insurance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback